Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Citi
Mallinckrodt
Boehringer Ingelheim
McKesson
Deloitte
McKinsey
Dow
Johnson and Johnson
Fish and Richardson
Cipla

Generated: October 20, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 208673

« Back to Dashboard
NDA 208673 describes SOLIQUA 100/33, which is a drug marketed by Sanofi-aventis Us and is included in one NDA. It is available from one supplier. There are twenty patents protecting this drug. Additional details are available on the SOLIQUA 100/33 profile page.

The generic ingredient in SOLIQUA 100/33 is insulin glargine; lixisenatide. There are thirty-eight drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the insulin glargine; lixisenatide profile page.

Summary for NDA: 208673

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:20
Formulation / Manufacturing:see details

Pharmacology for NDA: 208673

Suppliers and Packaging for NDA: 208673

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
SOLIQUA 100/33
insulin glargine; lixisenatide
SOLUTION;SUBCUTANEOUS 208673 NDA Sanofi-Aventis U.S. LLC 0024-5761 0024-5761-05 5 SYRINGE in 1 CARTON (0024-5761-05) > 3 mL in 1 SYRINGE

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;SUBCUTANEOUSStrength300 UNITS/3ML;99MCG/3ML (100 UNITS/ML;33MCG/ML)
Approval Date:Nov 21, 2016TE:RLD:Yes
Regulatory Exclusivity Expiration:Jul 27, 2021
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Regulatory Exclusivity Expiration:Nov 21, 2019
Regulatory Exclusivity Use:NEW COMBINATION
Patent:► SubscribePatent Expiration:Sep 23, 2027Product Flag?YSubstance Flag?Delist Request?


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cipla
Accenture
Novartis
US Department of Justice
Baxter
Express Scripts
Medtronic
Boehringer Ingelheim
Julphar
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot